Spots Global Cancer Trial Database for A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma
Official Title: An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of LP-168 Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma
Study ID: NCT05716087
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, single arm, multi-center Phase 2 study of oral LP-168 in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui provincial cancer hospital, Hefei, Anhui, China
The first affiliated hospital of Anhui medical university, Hefei, Anhui, China
Peking University Third Hospital, Beijing, Beijing, China
Beijing Cancer Hospital, Beijing, Beijing, China
The first affiliated hospital of Chongqing mediacal university, Chongqing, Chongqing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
Fujian Medical university union hospital, Fuzhou, Fujian, China
The first affiliated hospital of Xiamen university, Xiamen, Fujian, China
Gansu provincial cancer hospital, Lanzhou, Gansu, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Meizhou people'shospital, Meizhou, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
The fourth hospital of Hebei medical university, Shijia Zhuang, Hebei, China
Harbin First Hospital, Ha'erbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Henan provincial people's hospital, Zhengzhou, Henan, China
The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China
Hunan cancer hospital, Changsha, Hunan, China
Jiangsu cancer hospital, Nanjing, Jiangsu, China
Jiangsu province hospital, Nanjing, Jiangsu, China
The first affiliated hospital of Nanchang university, Nanchang, Jiangxi, China
The second hospital of dalian medical university, Dalian, Liaoning, China
Shengjing hospital of China medical university, Shenyang, Liaoning, China
The first hospital of China medical university, Shenyang, Liaoning, China
Qilu hospital of Shandong university, Jinan, Shandong, China
Shandong Cancer Hospital, Jinan, Shandong, China
West China School of Medicine, Chengdu, Sichuan, China
Tianjin Hematonosis Hospital, Tianjin, Tianjin, China
Tianjin medical university cancer hospital, Tianjin, Tianjin, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Affiliated hospital of hebei university, Baoding, , China
Beijing Boren Hospital, Beijing, , China
Beijing Friendship hospital, Beijing, , China
The First Bethune Hospital of Jilin University, Changchun, , China
Sichuan Cancer Hospital, Chengdu, , China
The First People's Hospital of Foshan, Foshan, , China
Nanfang Hospital, Southern Medical University, Guangzhou, , China
Sun Yat-sen Memorial Hospital, Guangzhou, , China
The First Affiliated Hospital of Soochow University, Suzhou, , China
The first affiliated hospital of Wenzhou medical university, Wenzhou, , China
Hubei Cancer Hospital, Wuhan, , China
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, , China
Contact Details
Name: Jun Zhu, MD, PhD
Affiliation: Peking University Cancer Hospital & Institute
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
